NEW YORK, April 12 – LabBook said Thursday it had reached an agreement to make John Wiley & Sons’ scientific content available through its Genomic XML Browser.
Under the terms of the deal, Wiley of New York has also acquired an equity stake in LabBook, marking the second equity investment in as many days that LabBook has announced.
On Wednesday, LabBook said IBM took an equity stake in the company as part of a strategic alliance to combine LabBook's desktop information retrieval, integration, mining, and visualization software with IBM's back-end data management, data integration, and Internet infrastructure software.
“Our overall strategy has been to partner with like-minded companies that are interested in providing an excellent environment for scientists,” said Adel Mikhail, vice president of corporate development at LabBook.
Mikhail declined to disclose the size of the equity stakes, but said Wiley’s stake was “substantial.”
Mikhail said the deal with Wiley would give LabBook customers access to the company’s 300 scientific, technical, and medical journals as well as its reference works and scientific protocols and allow them to combine the information with their own empirical data. The customers' accounts will remain with LabBook, which will share revenues with Wiley.
In addition to its genomic XML browser, LabBook has developed an extensible markup language for bioinformatics and a bioinformatics sequence markup language that are designed to retain semantic content, allowing researchers to derive more meaning from the data, Mikhail said.
Researchers can test LabBook’s genomic XML viewer for free at www.labbook.com .
Mikhail noted that the company was now looking to provide its technology to companies that offer genomic content.
LabBook expects to make several new announcements “very soon” regarding new customers and new features in its genomic browser, Mikhail said.
LabBook has offices in McLean, Va., and Columbus, Ohio.